Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta
- PMID: 34737005
- PMCID: PMC8559441
- DOI: 10.1016/j.jep.2021.114797
Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta
Abstract
Ethnopharmacological relevance: For millennia, Artemisia annua L. was used in Southeast Asia to treat "fever". This medicinal plant is effective against multiple pathogens and is used by many global communities as a source of artemisinin derivatives that are first-line drugs to treat malaria caused by Plasmodium parasites.
Aim of the study: The SARS-CoV-2 (Covid-19) global pandemic has killed millions and evolved numerous variants, with delta being the most transmissible to date and causing break-through infections of vaccinated individuals. We further queried the efficacy of A. annua cultivars against new variants.
Materials and methods: Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).
Results: In addition to being effective against the original wild type (WT) WA1, A. annua cultivars A3, BUR, MED, and SAM were also potent against all five variants. IC50 and IC90 values based on measured artemisinin content ranged from 0.3 to 8.4 μM and 1.4-25.0 μM, respectively. The IC50 and IC90 values based on dried leaf weight (DW) used to make the tea infusions ranged from 11.0 to 67.7 μg DW and 59.5-160.6 μg DW, respectively. Cell toxicity was insignificant at a leaf dry weight of ≤50 μg in the extract of any cultivar.
Conclusions: Results suggest that oral consumption of A. annua hot-water extracts (tea infusions) could potentially provide a cost-effective therapy to help stave off the rapid global spread of these variants, buying time for broader implementation of vaccines.
Keywords: Artemisinin; Covid-19; Delta variant; Gamma variant; Kappa variant; SARS-CoV-2.
Copyright © 2021 Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.J Ethnopharmacol. 2021 Jun 28;274:114016. doi: 10.1016/j.jep.2021.114016. Epub 2021 Mar 12. J Ethnopharmacol. 2021. PMID: 33716085 Free PMC article.
-
SARS-CoV-2 omicron variants are susceptible in vitro to Artemisia annua hot water extracts.J Ethnopharmacol. 2023 May 23;308:116291. doi: 10.1016/j.jep.2023.116291. Epub 2023 Feb 18. J Ethnopharmacol. 2023. PMID: 36804200 Free PMC article.
-
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.bioRxiv. 2021 Feb 24:2021.01.08.425825. doi: 10.1101/2021.01.08.425825. Preprint. bioRxiv. 2021. PMID: 33442683 Free PMC article. Updated.
-
Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?Molecules. 2022 Jun 14;27(12):3828. doi: 10.3390/molecules27123828. Molecules. 2022. PMID: 35744958 Free PMC article. Retracted. Review.
-
An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.J Integr Med. 2021 Sep;19(5):375-388. doi: 10.1016/j.joim.2021.07.003. Epub 2021 Jul 22. J Integr Med. 2021. PMID: 34479848 Free PMC article. Review.
Cited by
-
New clinical application prospects of artemisinin and its derivatives: a scoping review.Infect Dis Poverty. 2023 Dec 11;12(1):115. doi: 10.1186/s40249-023-01152-6. Infect Dis Poverty. 2023. PMID: 38072951 Free PMC article. Review.
-
An Estimation of the Antiviral Activity and Toxicity of Biologically Active Substances Obtained from the Raw Materials of Artemisia cina Berg. In Vitro and In Vivo.Molecules. 2023 Jul 14;28(14):5413. doi: 10.3390/molecules28145413. Molecules. 2023. PMID: 37513290 Free PMC article.
-
The mint versus Covid hypothesis.Med Hypotheses. 2023 Apr;173:111047. doi: 10.1016/j.mehy.2023.111047. Epub 2023 Mar 15. Med Hypotheses. 2023. PMID: 37007799
-
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.Life (Basel). 2023 Feb 23;13(3):617. doi: 10.3390/life13030617. Life (Basel). 2023. PMID: 36983772 Free PMC article. Review.
-
Artemisia afra and Artemisia annua Extracts Have Bactericidal Activity against Mycobacterium tuberculosis in Physiologically Relevant Carbon Sources and Hypoxia.Pathogens. 2023 Feb 1;12(2):227. doi: 10.3390/pathogens12020227. Pathogens. 2023. PMID: 36839499 Free PMC article.
References
-
- Cao R., Hu H., Li Y., Wang X., Xu M., Liu J., Zhang H., Yan Y., Zhao L., Li W. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect. Dis. 2020;6:2524–2531. - PubMed
-
- Gendrot M., Duflot I., Boxberger M., Delandre O., Jardot P., Le Bideau M., Andreani J., Fonta I., Mosnier J., Rolland C. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int. J. Infect. Dis. 2020;99:437–440. - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
